Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Hold at Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Other analysts also recently issued research reports about the stock. Piper Sandler assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday. They set an “overweight” rating and a $47.00 target price for the company. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Jefferies Financial Group assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday. They issued a “strong-buy” rating for the company. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $63.50.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $28.21 on Tuesday. The business has a 50-day moving average of $41.74 and a two-hundred day moving average of $47.04. The firm has a market capitalization of $3.33 billion, a PE ratio of 7.88 and a beta of 0.84. Supernus Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $42.81.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The firm had revenue of $208.60 million during the quarter, compared to analyst estimates of $217.56 million. During the same period in the prior year, the firm earned ($0.80) earnings per share. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. As a group, research analysts anticipate that Supernus Pharmaceuticals will post 3.66 earnings per share for the current year.

Institutional Trading of Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of SUPN. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $434,871,000. Bank of America Corp DE lifted its position in shares of Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after purchasing an additional 193,479 shares in the last quarter. Ashford Capital Management Inc. lifted its position in shares of Supernus Pharmaceuticals by 5.4% during the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock worth $33,360,000 after purchasing an additional 32,843 shares in the last quarter. Rice Hall James & Associates LLC acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth $22,800,000. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Supernus Pharmaceuticals by 0.6% in the third quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock valued at $19,116,000 after purchasing an additional 2,437 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

More Supernus Pharmaceuticals News

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.